Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAMOXI pilot study of tamoxifen protection during ovarian hyperstimulation for fertility preservation in estrogen receptor-positive breast cancer
NL-OMON35875Not yet recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tamoxifen in breast cancer, sponsored by Amsterdam University Medical Center. Primary endpoint: Serum endoxifen level during ovarian hyperstimulation. Planned start Feb 2011; status: not yet recruiting.
02
Drugs
tamoxifen
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON35875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35875.